These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37493797)

  • 1. Dipeptidyl-peptidase-4 inhibitors have anti-inflammatory effects in patients with type 2 diabetes.
    Xie D; Wang Q; Huang W; Zhao L
    Eur J Clin Pharmacol; 2023 Oct; 79(10):1291-1301. PubMed ID: 37493797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus.
    Zhao L; Meng J; Bai X; Zhang D; Yang X; Yang Y; Cai G; Liu X
    Eur J Med Res; 2024 Jul; 29(1):363. PubMed ID: 38997754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials.
    Atkin SL; Katsiki N; Banach M; Mikhailidis DP; Pirro M; Sahebkar A
    J Diabetes Complications; 2017 Sep; 31(9):1458-1464. PubMed ID: 28647512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.
    Meng J; Yan R; Zhang C; Bai X; Yang X; Yang Y; Feng T; Liu X
    Lipids Health Dis; 2023 Dec; 22(1):219. PubMed ID: 38082288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
    Liu X; Men P; Wang B; Cai G; Zhao Z
    Lipids Health Dis; 2019 Jun; 18(1):144. PubMed ID: 31208420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
    O'Hara DV; Parkhill TR; Badve SV; Jun M; Jardine MJ; Perkovic V
    Diabetes Obes Metab; 2021 Mar; 23(3):763-773. PubMed ID: 33269512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
    Chen Y; Men K; Li XF; Li J; Liu M; Fan ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3502-3514. PubMed ID: 29917205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
    Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
    Chai S; Zhang R; Zhang Y; Carr RD; Zheng Y; Rajpathak S; Ji L
    Front Endocrinol (Lausanne); 2022; 13():994944. PubMed ID: 36313782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Chai S; Zhang R; Zhang Y; Carr RD; Zheng Y; Rajpathak S; Yu M
    Front Endocrinol (Lausanne); 2022; 13():935039. PubMed ID: 36017316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.
    He L; Wang J; Ping F; Yang N; Huang J; Li W; Xu L; Zhang H; Li Y
    BMJ; 2022 Jun; 377():e068882. PubMed ID: 35764326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis.
    Guo W; Rathi S; Marquez J; Smith H; Kuruvilla A; Tonnesen MG; Salvemini JN
    Arch Dermatol Res; 2023 Oct; 315(8):2207-2213. PubMed ID: 36867222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in the Inpatient Setting.
    Petite SE; Hill MC
    J Pharm Pract; 2022 Apr; 35(2):229-234. PubMed ID: 33094657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure in Patients with Type 2 Diabetes?
    Hassanabad MF; Hassanabad AF; Fatehi M
    Curr Diabetes Rev; 2022; 18(8):e161221199093. PubMed ID: 34915838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
    Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
    Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
    Yang M; Wang L; Gu L; Yuan W
    J Diabetes; 2017 Dec; 9(12):1107-1117. PubMed ID: 28266136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.